keyword
MENU ▼
Read by QxMD icon Read
search

Semaglutide

keyword
https://www.readbyqxmd.com/read/29766634/semaglutide-induces-weight-loss-in-subjects-with-type-2-diabetes-regardless-of-baseline-bmi-or-gastrointestinal-adverse-events-in-sustain-1-5-trials
#1
Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John Ph Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence A Leiter
AIMS: Semaglutide, a new once-weekly glucagon-like peptide 1 analogue for the treatment of type 2 diabetes, demonstrated superior reductions in HbA1c and superior weight loss (by 2.3-6.3 kg) versus different comparators across the SUSTAIN 1-5 trials; the contributing factors to weight loss are not established. This post hoc analysis assessed the effect of baseline body mass index (BMI), and of occurrence of nausea and/or vomiting, on semaglutide-induced weight loss. MATERIALS AND METHODS: Subjects with inadequately controlled type 2 diabetes (drug-naïve or on background treatment) were randomized to subcutaneous semaglutide 0...
May 15, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29764222/comparative-efficacy-of-once-weekly-semaglutide-and-sglt-2-inhibitors-in-type-2-diabetic-patients-inadequately-controlled-with-metformin-monotherapy-a-systematic-literature-review-and-network-meta-analysis
#2
Rohini Sharma, Lars Wilkinson, Hrvoje Vrazic, Evan Popoff, Sandra Lopes, Steve Kanters, Eric Druyts
OBJECTIVE: Treatment intensification with additional antidiabetic agents is recommended in type 2 diabetes (T2D) for patients inadequately controlled on metformin monotherapy. The present network meta-analysis (NMA) evaluated comparative efficacy and safety of once-weekly semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in T2D patients inadequately controlled with metformin. METHODS: Randomized controlled trials with ≥20 weeks duration were searched in EMBASE, MEDLINE, and CENTRAL...
May 15, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29756388/semaglutide-for-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#3
Panagiotis Andreadis, Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Manolopoulos, Eleni Bekiari, David R Matthews, Apostolos Tsapas
AIM: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. METHODS: We searched major electronic databases and grey literature sources for randomised controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c . Secondary endpoints included change from baseline in body weight, blood pressure, heart rate, and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy...
May 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29748996/exposure-response-analysis-for-evaluation-of-semaglutide-dose-levels-in-type-2-diabetes
#4
Kristin C C Petri, Steen H Ingwersen, Anne Flint, Jeppe Zacho, Rune V Overgaard
AIMS: Semaglutide is a glucagon-like peptide-1 analogue approved for the treatment of type 2 diabetes. To evaluate dose levels, we examined the effects of demographic factors on efficacy and safety in an exposure-response analysis. METHODS: We analysed data from 1552 adults from four randomised phase 3 trials of 30-56 weeks' duration investigating once-weekly semaglutide doses 0.5 and 1.0 mg. Exposure-response relationships were investigated using graphical and model-based techniques to assess the two dose levels and subgroups with the highest and lowest exposure and response...
May 11, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29748368/cardiovascular-effects-of-new-oral-glucose-lowering-agents-dpp-4-and-sglt-2-inhibitors
#5
REVIEW
André J Scheen
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with liraglutide and semaglutide, 2 glucagon-like peptide-1 receptor agonists, and with empagliflozin and canagliflozin, 2 SGLT-2 (sodium-glucose cotransporter type 2) inhibitors, but not with DPP-4 (dipeptidyl peptidase-4) inhibitors. The present review is devoted to CV effects of new oral glucose-lowering agents...
May 11, 2018: Circulation Research
https://www.readbyqxmd.com/read/29739505/semaglutide-ertugliflozin-and-deflazacort
#6
Daniel A Hussar, Kaitlyn J Bailey
No abstract text is available yet for this article.
May 2018: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/29713961/a-systematic-literature-review-and-network-meta-analysis-comparing-once-weekly-semaglutide-with-other-glp-1-receptor-agonists-in-patients-with-type-2-diabetes-previously-receiving-basal-insulin
#7
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic
INTRODUCTION: Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other GLP-1 receptor agonists (GLP-1 RAs) is available. The aim of this study was to conduct a network meta-analysis (NMA) to assess the efficacy and safety of once-weekly semaglutide vs other GLP-1 RAs in patients with T2D inadequately controlled on basal insulin...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29707863/glucagon-like-peptide-1-receptor-expression-in-the-human-eye
#8
Josephine B Hebsgaard, Charles Pyke, Emre Yildirim, Lotte B Knudsen, Steffen Heegaard, Peter H Kvist
Semaglutide is a human glucagon-like peptide-1 (GLP-1) analog that is in development for the treatment of type 2 diabetes. In the pre-approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy complications versus placebo. GLP-1 receptor (GLP-1R) expression has previously been demonstrated in the retina in animals and humans. However, antibodies used to detect expression have been documented to be non-specific and fail to detect the GLP-1R using immunohistochemistry (IHC), a problem common for many G-protein coupled receptors...
April 29, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29702499/new-antihyperglycaemic-agents-and-cardiovascular-disease-let-s-be-optimistic
#9
Kalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas
PURPOSE OF REVIEW: Cardiovascular disease (CVD) substantially increases mortality in diabetes mellitus. This narrative review highlights recent research on the putative associations between dipeptyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter 2 inhibitors (SGLT-2is) and several cardiovascular risk factors. RECENT FINDINGS: New antihyperglycaemic agents favourably modulate several CVD risk factors, including fasting and postprandial plasma glucose levels, body weight, blood pressure, lipids, microalbuminuria, nonalcoholic fatty liver disease, serum uric acid, and arterial stiffness...
April 26, 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29693715/pharmacokinetics-safety-and-tolerability-of-oral-semaglutide-in-subjects-with-hepatic-impairment
#10
Tine A Baekdal, Mette Thomsen, Viera Kupčová, Cilie W Hansen, Thomas W Anderson
Semaglutide is a human glucagon-like peptide-1 analog that has been co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of oral semaglutide. Subjects were classified into groups: normal hepatic function (n = 24), and mild (n = 12), moderate (n = 12), or severe (n = 8) hepatic impairment according to Child-Pugh criteria, and received once-daily oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)...
April 25, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29693361/generalizability-of-glucagon-like-peptide-1-receptor-agonist-cardiovascular-outcome-trials-enrollment-criteria-to-the-us-type-2-diabetes-population
#11
Eric T Wittbrodt, James M Eudicone, Kelly F Bell, Devin M Enhoffer, Keith Latham, Jennifer B Green
OBJECTIVES: Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general population. This study examined the proportion of adults eligible for 7 ongoing or completed glucagon-like peptide-1 receptor agonist (GLP-1 RA) CVOTs. STUDY DESIGN: This cross-sectional, retrospective, cohort study compared data from the National Health and Nutrition Examination Survey (NHANES) with published eligibility criteria from GLP-1 RA CVOTs...
April 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29688502/semaglutide-added-to-basal-insulin-in-type-2-diabetes-sustain-5-a-randomised-controlled-trial
#12
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood
Context: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasingly important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. Objective: To demonstrate the superiority of semaglutide versus placebo on glycaemic control as add-on to basal insulin in patients with T2D. Design: Phase 3a, double blind, placebo-controlled, 30-week trial...
April 23, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29687620/semaglutide-as-a-therapeutic-option-for-elderly-patients-with-type-2-diabetes-pooled-analysis-of-the-sustain-1-5-trials
#13
Mark Warren, Louis Chaykin, David Trachtenbarg, Gurudutt Nayak, Nelun Wijayasinghe, Bertrand Cariou
This pooled analysis evaluated the efficacy and safety of semaglutide vs comparators in non-elderly (<65 years) and elderly (≥65 years) patients with type 2 diabetes (T2D) across the SUSTAIN 1-5 trials. Patients were randomised to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin. Primary objective was change in HbA1c ; secondary objectives were change in body weight and safety. Mean HbA1c decreased from baseline by 1.2-1.5% and 1.5-1.9% vs 0.0-0.9% (non-elderly, n=3,045) and by 1...
April 23, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29677253/in-type-2-diabetes-weekly-semaglutide-reduced-hba1c-and-increased-weight-loss-more-than-weekly-exenatide-er
#14
Eleni Bekiari, Thomas Karagiannis, Apostolos Tsapas
No abstract text is available yet for this article.
April 17, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29675798/a-systematic-literature-review-and-network-meta-analysis-comparing-once-weekly-semaglutide-with-other-glp-1-receptor-agonists-in-patients-with-type-2-diabetes-previously-receiving-1-2-oral-anti-diabetic-drugs
#15
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic
INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1-2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) inadequately controlled on 1-2 OADs...
April 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29668601/efficacy-and-safety-of-once-weekly-semaglutide-for-the-treatment-of-type-2-diabetes-protocol-for-a-systematic-review-and-meta-analysis
#16
REVIEW
Fang-Hong Shi, Hao Li, Min Cui, Zai-Li Zhang, Zhi-Chun Gu, Xiao-Yan Liu
BACKGROUND: It is a great challenge for type 2 diabetes mellitus (T2DM) patients to maintain optimal glycemia, control body weight, blood pressure, and avoiding hypoglycemia. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) can stimulate glucose-dependent insulin while inhibit glucagon secretion, delay gastric emptying, reduce appetite, and energy intake. Recently, a new once-weekly GLP-1 RAs, semaglutide, has been registered to treat patients with T2DM. METHODS: We will search Medline, Embase, Cochrane Library, and the ClinicalTrials...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29667921/glycemic-control-of-type-2-diabetes-mellitus-across-stages-of-renal-impairment-information-for-primary-care-providers
#17
Lili Tong, Sharon Adler
Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM) and elevates individuals' risk for cardiovascular disease, the leading cause of morbidity and mortality in T2DM. Achieving and maintaining tight glycemic control is key to preventing development or progression of CKD; however, improving glycemic control may be limited by effects of renal impairment on the efficacy and safety of T2DM treatments, necessitating dosing adjustments and careful evaluation of contraindications...
April 18, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29623579/pharmacokinetics-safety-and-tolerability-of-oral-semaglutide-in-subjects-with-renal-impairment
#18
Charlotte Granhall, Flemming L Søndergaard, Mette Thomsen, Thomas W Anderson
BACKGROUND: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) as a tablet for oral administration. This trial (NCT02014259) investigated the pharmacokinetics, safety and tolerability of oral semaglutide in subjects with and without renal impairment. METHODS: Subjects were categorised as having normal renal function (n = 24), mild (n = 12), moderate (n = 12) or severe (n = 12) renal impairment, or end-stage renal disease (ESRD) requiring haemodialysis (n = 11) and received once-daily oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days) in the fasting state, followed by 30 min fasting after dosing...
April 6, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29611550/erratum-to-semaglutide-seems-to-be-more-effective-the-other-glp-1ras
#19
Jens Juul Holst, Sten Madsbad
[This corrects the article on p. 505 in vol. 5, PMID: 29299466.].
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29580579/new-glucose-lowering-agents-for-diabetic-kidney-disease
#20
REVIEW
Lisanne C de Vos, Thushan S Hettige, Mark E Cooper
The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents...
March 2018: Advances in Chronic Kidney Disease
keyword
keyword
25760
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"